Wednesday, 30 April 2014

» Drisapersen update from Prosensa Action Duchenne

» Drisapersen update from Prosensa Action Duchenne: "Prosensa issued an update today to the parent-led organisations on their lead exon skipping compound to skip exon 51, drisapersen; following their recent UPPMD webinar on the 25th of March.
Whilst Prosensa are finalising the transfer from GSK, they also continue to embark on their program to re-dosing the first cohort of boys who participated in the trial in the third quarter of this year and also communicating their plans and regulatory paths forward forward, by the end of June."



'via Blog this'

No comments:

Post a comment